Isabelle Cadron

Post-hoc analysis evaluating selinexor maintenance therapy in patients with TP53 wt endometrial cancer: Progression-free survival by clinical factors in the ENGOT-EN5/GOG-3055/SIENDO study.

Jalid Sehouli, Ignace B. Vergote, Erika Paige Hamilton, José Alejandro Pérez Fidalgo et autres

5608 Background: At primary analysis of the phase 3 study of selinexor (SEL) maintenance treatment in patients (pts) with advanced/recurrent endometrial cancer (EC), improvement in median progression-free survival (PFS) for the intent-to-treat population was not clinically meaningful. However, a promising efficacy signal …

de, be, us, es, it, cz, il, ca (code pays fourni par la source)

Preoperative tumour size assessment in patients with early-stage cervical cancer: Final results of the SENTIX study

Martina Borčinová, Christhardt Köhler, Kristýna Němejcová, Ignacio Zapardiel et autres

cz, de, es, hu, pl, at, sk, be, ch (code pays fourni par la source)

Longer-Term Safety And Efficacy Of Selinexor Maintenance Therapy For Patients With TP53wt Advanced Or Recurrent Endometrial Cancer: Follow-Up Subgroup Analysis Of The ENGOT-EN5/GOG-3055/SIENDO Study

Giorgio Valabrega, Ignace B. Vergote, Debra L. Richardson, José Alejandro Pérez Fidalgo et autres

it, be, us, es, de, cz, il, ca (code pays fourni par la source)

Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer

Ignace B. Vergote, José Alejandro Pérez Fidalgo, Erika Paige Hamilton, Giorgio Valabrega et autres

PURPOSE Selinexor inhibits exportin-1 (XPO1) resulting in nuclear accumulation of tumor suppressor proteins including p53 and has clinical activity in endometrial cancer (EC). The primary end point was to assess progression-free survival (PFS) with once-weekly oral selinexor in patients with advanced or …

be, es, us, it, de, cz, il, ca, dk (code pays fourni par la source)

Intrauterine device (IUD) migration in cesarean delivery scar: What to do with the niche?

A Verest, E Borwski, Isabelle Cadron, S. Van Calenbergh et autres

BACKGROUND: The presence of a niche after cesarean section is a common and mostly asymptomatic finding. However, it can cause symptoms or result in impaired fertility or obstetric complications in following pregnancies. At present there is no uniform consensus on when to …

be (code pays fourni par la source)

Proteomics in Gynaecologic Oncology

Toon Van Gorp, Isabelle Cadron, Ignace B. Vergote

The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma — Analysis of patient data in the prospective OVCAD study

Gerda Hofstetter, Nicole Concin, Elena Ioana Braicu, Radoslav Chekerov et autres

at, de (code pays fourni par la source)

Outcome and Clinical Management of 275 Patients With Advanced Ovarian Cancer International Federation of Obstetrics and Gynecology II to IV Inside the European Ovarian Cancer Translational Research Consortium—OVCAD

Radoslav Chekerov, Elena Ioana Braicu, Dan Cacsire Castillo‐Tong, Rolf Richter et autres

de, at, be, nl (code pays fourni par la source)

The “Leuven” paclitaxel/carboplatin weekly regimen in patients with recurrent ovarian cancer, a retrospective study

Isabelle Cadron, Leyla Abdulkadir, Evelyn Despierre, Patrick Berteloot et autres

be (code pays fourni par la source)

Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer—a study by the OVCAD consortium

Andreas Melmer, Linda Fineder, Claudia Lamina, Barbara Kollerits et autres

at, de, be (code pays fourni par la source)

Use of HE4 and CA125 to predict surgical outcome and for prognostic value for progression-free survival (PFS) and overall survival (OS) in primary epithelial ovarian cancer (EOC) patients (pts).

Elena Ioana Braicu, Radoslav Chekerov, Rolf Richter, Ignace B. Vergote et autres

5034 Background: Optimal surgical cytoreduction and response to platinum (P) based chemotherapy (ChTh) remain the cornerstones of therapeutic management of primary EOC. Aim of this study was to analyze the predictive role of HE4 and CA125 as biomarkers (BM) for clinical outcome …

de, be, at, us (code pays fourni par la source)

Interval versus primary tumor debulking surgery in advanced ovarian cancer: Analysis of the European OVCAD data.

Christina Fotopoulou, Elena Ioana Braicu, Ignace B. Vergote, Isabelle Cadron et autres

5071 Background: The international scenery around optimal primary treatment of advanced ovarian cancer (AOC) patients (pts) is currently being discussed, with large discrepancies and heterogeneity still existing between the national guidelines worldwide. Aim of the present study was to evaluate the differences …

de, be, at (code pays fourni par la source)